Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Prostatic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 5Trastuzumab 4Taxes 4Docetaxel 4Paclitaxel 3Albumin-Bound Paclitaxel 3tipifarnib 2sargramostim 2liposomal doxorubicin 2Vorinostat 2Immunohistochemistry 2Granulocyte-Macrophage Colony-Stimulating Factor 2Filgrastim 2Enzyme-Linked Immunosorbent Assay 2Doxorubicin 2Capecitabine 2temsirolimus 1seviteronel 1romidepsin 1poly(I).poly(c12,U) 1pertuzumab 1pegfilgrastim 1oblimersen 1ixabepilone 1interferon gamma-1b 1flt3 ligand protein 1denileukin diftitox 1cixutumumab 1alvocidib 1Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms, Male × ixabepilone × Clear all
NCT00765765 2023-08-09

Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer

Rutgers, The State University of New Jersey

Phase 1/2 Terminated
6 enrolled 7 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡